The Medical Letter on Drugs and Therapeutics
Deucravacitinib (Sotyktu) for Plaque Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Deucravacitinib (Sotyktu) for Plaque Psoriasis
The FDA has approved deucravacitinib (Sotyktu – BMS), an oral tyrosine kinase 2 (TYK2) inhibitor, for once-daily treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Deucravacitinib (Sotyktu) for Plaque Psoriasis
Article code: 1670b
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.